原发性肝癌患者服用索拉非尼前后血清bFGF浓度变化
被引量:2
摘要
目的探讨原发性肝癌患者索拉非尼治疗前后血清碱性纤维母细胞生长因子(bFGF)的变化及其临床意义。方法采用双抗体夹心酶联免疫法(ELISA)测定64例原发性肝癌患者行索拉非尼治疗前后血清bFGF的含量比较分析。结果行索拉非尼治疗后,患者血清bFGF含量降低(P<0.05)。结论索拉非尼治疗能抑制肝癌肿瘤的浸润和转移。
出处
《齐齐哈尔医学院学报》
2010年第18期2899-2899,共1页
Journal of Qiqihar Medical University
参考文献5
-
1张晶晶,王波,刘增娟.腹膜间皮细胞对卵巢癌细胞血管生成因子表达及分泌的影响[J].中华肿瘤杂志,2006,28(10):737-740. 被引量:3
-
2Dietz,Rudat V,Conradt C,et al.Prognostic relevance of serumlevels of the angiogenic peptide bFGF in advanced carcinoma ofthe head and neck treated by primary radio-chemotherapy[J].Head Neck,2000,22(7):666-673.
-
3Obermair A,Speiser P,Reisenberger K,et al.Influence ofintratu-moral basic fibroblast growth factor concentration on survival in o-varian cancer patients[J].Cancer Lett,1998,130(1-2):69-76.
-
4Llovet J,Ricci S,Mazzaferro V,et al.Sorafenib in advanced Hepatocellular Carcinoma[J].N Engl J Med,2008,359(4):378-390.
-
5Cheng AL,Kang Y,Chen Z,et al.Randomized phase nI trial of sorafenib versI1s placebo in Asian patients with advanced hepa-tocellular carcinoma[J].Journal of Clinical Oneology,2008,26(19 Supp1):4509.
二级参考文献8
-
1Liss C,Fekete MJ,Hasina R,et al.Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages.Int J Cancer,2001,93:781-785.
-
2Aoyagi K,Kouhuji K,Yano S,et al.VEGF significance in peritoneal recurrence from gastric cancer.Gastric Cancer,2005,8:155-163.
-
3Carpenter PM,Dao AV.The role of hyaluronan in mesotheliuminduced motility of ovarian carcinoma cells.Anticancer Res,2003,23:3985-3990.
-
4Hirashima Y,Kobayashi H,Suzuki M,et al.Transforming growth factor-β1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.J Biol Chem,2003,278:26793-26802.
-
5Yao V,Platell C,Hall JC.Peritoneal mesothelial cells produce inflammatory related cytokines.ANZ J Surg,2004,74:997-1002.
-
6Lee HT,Lee JG,Na M,et al.FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells.J Biol Chem,2004,279:32325-32332.
-
7郭群英,叶任高,黄凌虹,郑树森,汪涛.透明质酸合成酶-2在人腹膜间皮细胞透明质酸合成及胞外基质形成中的作用[J].中华肾脏病杂志,2002,18(5):331-336. 被引量:9
-
8林卫,彭芝兰,王光林,毕建红,刘珊玲,王红静.bFGF-MAb抑制卵巢癌细胞及其腹腔移植瘤生长的实验研究[J].四川大学学报(医学版),2003,34(4):625-627. 被引量:4
共引文献2
-
1何晓武,张卫民,刘海俊.介入治疗对胰腺癌患者血清bFGF、ColⅣ、HA的影响[J].中国热带医学,2008,8(5):793-795. 被引量:1
-
2王前,李新国,张怡,曹兰琴,邓征浩,陈勇.卵巢癌组织中EVEC的表达及其生物学意义[J].中华肿瘤杂志,2010,32(9):676-680. 被引量:4
同被引文献26
-
1Llovet JM,Ricci S,Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma[J].New England Journal of Medicine,2008,(04):378-390.
-
2Wilhelm SM,Carter C,Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Research,2004,(19):7099-7109.doi:10.1158/0008-5472.CAN-04-1443.
-
3Liu L,Cao Y,Chen C. Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Research,2006,(24):11851-11858.
-
4Zhou C,Liu J,Li Y. microRNA-1274a,a modulator of sorafenib induced a disintegrin and metalloproteinase 9(ADAM9) down-regulation in hepatocellular carcinoma[J].FEBS Letters,2011,(12):1828-1834.
-
5Liu H,Peng HW,Cheng YS. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP[J].Molecular and Cellular Biology,2005,(08):3117-3126.doi:10.1128/MCB.25.8.3117-3126.2005.
-
6Fleischer B,Schulze-Bergkamen H,Schuchmann M. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma[J].International Journal of Oncology,2006,(01):25-32.
-
7Sieghart W,Losert D,Strommer S. Mcl-1 overexpression in hepatocellular carcinoma:a potential target for antisense therapy[J].Journal of Hepatology,2006,(01):151-157.
-
8Yamazaki K,Nagao T,Yamaguchi T. Expression of basic fibroblast growth factor(bFGF-2) -associated with tumor proliferation in human pancreatic carcinoma[J].VIRCHOWS ARCHIV-AN INTERNATIONAL Journal OF PATHOLOGY,1997,(02):95-101.
-
9Obermair A,Speiser P,Reisenberger K. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients[J].Cancer Letters,1998,(1/2):69-76.
-
10Park JI,Lee MG,Cho K. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2,p38-NF-kappaB,JNK,and Ras signaling pathways[J].Oncogene,2003,(28):4314-4332.
引证文献2
-
1廖于,李照东,左的于,刘宇,晏勇,左国庆.索拉非尼诱导HepG2细胞凋亡过程中Mcl-1与bFGF-2的表达及意义[J].重庆医学,2013,42(3):255-257. 被引量:3
-
2刘彦森,马桂玲,李丹,崔凯.不同介入疗法对胃癌肝转移瘤疗效的探讨[J].中外医疗,2014,33(24):78-79. 被引量:2
二级引证文献5
-
1赵建龙,占辉,杨月,李文哲,王中辉,邱相君.索拉非尼的临床应用和药物相互作用[J].中国临床药理学杂志,2014,30(10):958-961. 被引量:6
-
2郭志远,付吕平,付志国,康振桥,祁卫华.重组人血管内皮抑制素对小鼠胃癌c-Myc,bFGF表达的影响[J].标记免疫分析与临床,2015,22(9):916-920. 被引量:9
-
3王刚.肝动脉化疗栓塞术对富血供肝转移瘤的疗效分析[J].当代医学,2016,22(31):55-56. 被引量:2
-
4廖萍,廖宝兰,钟周华.四维超声检测胎儿三尖瓣反流及卵圆孔血流的临床价值[J].当代医学,2016,22(31):56-57. 被引量:3
-
5徐颖洁(综述),刘明慧,陈佳婧,韩云标,丁奕文,朱瑞颖,陆靖(审校).IL-6/STAT3信号通路介导索拉非尼治疗原发性肝癌耐药机制的研究进展[J].现代医药卫生,2024,40(17):3017-3022.
-
1左明鲜,孙林,张戈,周旭,章体玲,白文伟,光雪峰,杨达宽.血清bFGF水平与冠状动脉病变程度的关系[J].中国心血管病研究,2008,6(4):252-253. 被引量:1
-
2李刚.冠心病患者介入治疗前后血管内皮生长因子的变化及其临床意义[J].中外医疗,2013,32(34):19-19.
-
3杜习智,王豫辉,董根山,王爱风,孟宪丽,李瑞敏,王留义.阿托伐他汀对急性冠状动脉综合征早期血脂和炎症因子的影响[J].陕西医学杂志,2006,35(12):1600-1602. 被引量:6
-
4薛浩,崔秋英,李卫菊,刘国树,惠汝太.转化生长因子β_1与高血压肾损害的相关性研究[J].中国综合临床,2007,23(8):676-678. 被引量:1
-
5张国珍.消化性溃疡患者HP感染与IL-6、IL-8、IL-18的关系研究[J].当代医学,2014,20(1):91-92. 被引量:2
-
6关文利,甘宇,李铁男,于黎丽,郑长虹,贾鹏,张继斌,陈盛业.自体骨髓干细胞移植治疗糖尿病足溃疡的疗效及其与血清bFGF水平关系的研究[J].中国中西医结合皮肤性病学杂志,2011,10(2):90-92. 被引量:1
-
7许会彬,曹英林,张代民,杜遵民,王援朝,王化芬,李萍,崔庆.血清碱性成纤维细胞生长因子检测在急性淋巴细胞白血病中的临床意义[J].临床军医杂志,2005,33(1):16-18.
-
8李培英,林闽溪,沈庆乐,林美明,陈云龙.碱性成纤维细胞生长因子对原发性高血压患者颈动脉粥样硬化斑块的影响[J].实用中西医结合临床,2014,14(1):5-6. 被引量:1
-
9朱德文.联合检测血清bFGF、抗CCP抗体和RF在类风湿关节炎早期诊断的意义[J].实用临床医药杂志,2010,14(12):107-108. 被引量:4
-
10康海燕,董江龙,杨静,王艳,崔美兰,耿惠杰,王晓静.医用臭氧对聚乙二醇干扰素治疗慢性乙型肝炎疗效的影响[J].山东医药,2016,56(9):88-90. 被引量:7